Description
LIMKi 3 is a potent, and cell-permeable inhibitor of LIMK1 (IC₅₀ = 7 nM) and LIMK2 (IC₅₀ = 8 nM) and inhibits coflin phosphorylation in MDA-MB-231 breast cancer cells without affecting tubulin polymerization or inducing cytotoxicity. It also reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.
LIMKi 3 is a potent, and cell-permeable inhibitor of LIMK1 (IC₅₀ = 7 nM) and LIMK2 (IC₅₀ = 8 nM) and inhibits coflin phosphorylation in MDA-MB-231 breast cancer cells without affecting tubulin polymerization or inducing cytotoxicity. It also reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.
Alternate Name/Synonyms: N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide ; BMS 5
Appearance: White Solid
Formulation: N/A
CAS Number: 1338247-35-0
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₇H₁₄Cl₂F₂N₄OS
Molecular Weight: 431.29
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (>40mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: LIMKi 3 is a potent inhibitor of LIMK1 and LIMK2
MDL Number: N/A
PubChem CID: 56965901
SMILES: CC(C)C(=O)NC1=NC=C(S1)C2=CC(=NN2C3=C(C=CC=C3Cl)Cl)C(F)F
InChi: InChI=1S/C17H14Cl2F2N4OS/c1-8(2)16(26)23-17-22-7-13(27-17)12-6-11(15(20)21)24-25(12)14-9(18)4-3-5-10(14)19/h3-8,15H,1-2H3,(H,22,23,26)
InChi Key: IVUGBSGLHRJSSP-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |